Shiva Samavat

Dr. Shiva Samavat


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SKShiva Kalantari
Shiva Kalantari
DRDorothea Rutishauser
Dorothea Rutishauser
SSShiva Samavat
Shiva Samavat
MNMohsen Nafar
Mohsen Nafar
LMLeyla Mahmudieh
Leyla Mahmudieh
JZJanet Zubarev
Janet Zubarev
IgA nephropathy is the most common cause of primary glomerulonephritis. There are different pathologic biopsy-based scoring systems in use, but there is no consensus among nephrologists yet regarding the best classification method. Our aim was to test urine proteomics as a non-invasive method for classification of IgA nephropathy. This aim was pursued by discovering novel prognostic protein biomarkers in urine, and linking them to pathogenesis of the disease through known signaling and metabolic pathways. 13 urine samples of the patients with biopsy-proven IgA nephropathy were analyzed via two proteomics approaches: nanoflow LC-MS/MS and GeLC-MS/MS. The results of label-free quantification were subjected to multivariate statistical analysis, which could classify patients into two groups, broadly corresponding to the primary and advance stages. The proteome classification correlated well with biopsy-based scoring systems, especially endocapillary hypercellularity score of the Oxford’s classification. Differentially excreted candidate proteins were found as potential prognostic biomarkers: afamin, leucine-rich alpha-2-glycoprotein, ceruloplasmin, alpha-1-microgolbulin, hemopexin, apolipoprotein A-I, complement C3, vitamin D-binding protein, beta-2-microglobulin, and retinol-binding protein 4. Pathway analysis suggested impairment of Extra Cellular Matrix (ECM)-Receptor Interaction pathways as well as activation of complement and coagulation pathway in progression of IgA nephropathy.

1 December 2017 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
FSFariba Samadian
Fariba Samadian
NDNooshin Dalili
Nooshin Dalili
FGFatemeh Poor -Reza Gholi
Fatemeh Poor -Reza Gholi
MFMahtab Fattah
Mahtab Fattah
NMNarges Malih
Narges Malih
SZShadi Ziaie
Shadi Ziaie

1 November 2011
Verified
Journal Article
Closed access
MNMohsen Nafar
Mohsen Nafar
ZSZahra Sahraei
Zahra Sahraei
JSJamshid Salamzadeh
Jamshid Salamzadeh
SSShiva Samavat
Shiva Samavat
NVNosartolah D Vaziri
Nosartolah D Vaziri

2 September 2014 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
SKShiva Kalantari
Shiva Kalantari
MNMohsen Nafar
Mohsen Nafar
DRDorothea Rutishauser
Dorothea Rutishauser
SSShiva Samavat
Shiva Samavat
MRMostafa Rezaei-Tavirani
Mostafa Rezaei-Tavirani
JZJanet Zubarev
Janet Zubarev
Focal segmental glomerulosclerosis (FSGS) is a glomerular scarring disease diagnosed mostly by kidney biopsy. Since there is currently no diagnostic test that can accurately predict steroid responsiveness in FSGS, prediction of the responsiveness of patients to steroid therapy with noninvasive means has become a critical issue. In the present study urinary proteomics was used as a noninvasive tool to discover potential predictive biomarkers.

2 March 2017 in Magnetic Resonance in Chemistry
Verified
Journal Article
Closed access
PDF file
SKShiva Kalantari
Shiva Kalantari
MNMohsen Nafar
Mohsen Nafar
SSShiva Samavat
Shiva Samavat
MPMahmoud Parvin
Mahmoud Parvin

26 March 2014 in International Journal of Nephrology
Verified
Journal Article
Open access
PDF file
MNMohsen Nafar
Mohsen Nafar
SKShiva Kalantari
Shiva Kalantari
SSShiva Samavat
Shiva Samavat
MRMostafa Rezaei-Tavirani
Mostafa Rezaei-Tavirani
DRDorothea Rutishauser
Dorothea Rutishauser
JZJanet Zubarev
Janet Zubarev
Background. Focal segmental glomerulosclerosis (FSGS) is a glomerular injury with various pathogenic mechanisms. Urine proteome panel might help in noninvasive diagnosis and better understanding of pathogenesis of FSGS.Method. We have analyzed the urine sample of 11 biopsy-proven FSGS subjects, 8 healthy controls, and 6 patients with biopsy-proven IgA nephropathy (disease controls) by means of liquid chromatography tandem mass spectrometry (nLC-MS/MS). Multivariate analysis of quantified proteins was performed by principal component analysis (PCA) and partial least squares (PLS).Results. Of the total number of 389 proteins, after multivariate analysis and additional filter criterion and comparing FSGS versus IgA nephropathy and healthy subjects, 77 proteins were considered as putative biomarkers of FSGS. CD59, CD44, IBP7, Robo4, and DPEP1 were the most significant differentially expressed proteins. These proteins are involved in pathogenic pathways: complement pathway, sclerosis, cell proliferation, actin cytoskeleton remodeling, and activity of TRPC6.There was complete absence of DPEP1 in urine proteome of FSGS subjects compared with healthy and disease controls. DPEP1 acts via leukotrienes on TRPC6 and results in increased podocyte motility and proteinuria.Conclusion. The results suggest a panel of candidate biomarkers for noninvasive diagnosis of FSGS, while complete absence of DPEP1 might represent a novel marker of FSGS.